TRVI
Trevi Therapeutics, Inc.NASDAQHealthcare$11.94+3.11%ClosedMarket Cap: $1.53B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
10.17
P/S
0.00
EV/EBITDA
-36.50
DCF Value
$0.11
FCF Yield
-1.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-25.5%
ROA
-22.1%
ROIC
-26.8%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-10.2M | $-8.3M | $-0.06 | — |
| FY 2025 | $0.00 | -Infinity% | $-49.3M | $-42.8M | $-0.29 | — |
| Q3 2025 | $0.00 | NaN% | $-13.9M | $-11.8M | $-0.08 | — |
| Q2 2025 | $0.00 | NaN% | $-13.7M | $-12.3M | $-0.09 | — |
| Q1 2025 | $0.00 | NaN% | $-11.5M | $-10.3M | $-0.09 | — |
| Q4 2024 | $0.00 | -Infinity% | $-12.2M | $-11.4M | $-0.11 | — |
| FY 2024 | $0.00 | NaN% | $-51.5M | $-47.9M | $-0.47 | — |
| Q3 2024 | $0.00 | NaN% | $-14.1M | $-13.2M | $-0.13 | — |
| Q2 2024 | $0.00 | -Infinity% | $-13.3M | $-12.4M | $-0.12 | — |
| Q1 2024 | $0.00 | -Infinity% | $-11.9M | $-10.9M | $-0.11 | — |
| Q4 2023 | $0.00 | -Infinity% | $-8.9M | $-7.8M | $-0.08 | — |
| FY 2023 | $0.00 | NaN% | $-33.9M | $-29.1M | $-0.29 | — |